+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 13 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are evaluating molnupiravir, a study medicine designed to stop the COVID-19 virus from multiplying, to see if it can prevent severe illness from COVID-19 more effectively than a placebo in people who are at high risk. The focus is on non-hospitalized adults with COVID-19 who have certain health conditions or factors that increase their chance of severe illness, which can require hospitalization or lead to death. Participants will be randomly assigned to receive either 800 mg of molnupiravir orally every 12 hours for 5 days a total of 10 doses or a matching placebo on the same schedule. Some participants may also receive remdesivir as standard care if clinically appropriate. This is a phase 3, double-blind, placebo-controlled study comparing molnupiravir versus placebo. During the study, participants will be monitored for up to 29 days for outcomes such as hospitalization, death, and COVID-19-related medically attended visits. Researchers will assess adverse events and discontinuation due to side effects over approximately 5 months. Other measures include tracking symptom relief, changes in virus levels, and need for medical interventions. The total participation duration covers treatment and follow-up monitoring to evaluate safety and effectiveness.

Age: 18Years +All GendersPhase 3
227 locations
E

Actively Recruiting

This research aims to evaluate the effects of a 12-week adapted table tennis program on the physical and mental health of adults with disabilities. Although sports participation among individuals with disabilities has increased due to medical advances and greater societal awareness, about 60% still do not engage in regular physical activity. The study seeks to fill the research gap on the health benefits of adapted table tennis, a sport known for its versatility and accessibility. Participants in the study will either join weekly 2-hour group table tennis sessions led by a professional adapted sports coach for 12 weeks or continue with their usual medical care without exercise training. The sessions will include warm-up exercises, basic techniques, skill practice, and cool-down stretches. Two groups are compared those receiving the adapted training and a control group receiving no exercise intervention. Throughout the study, researchers will assess participants before the program, immediately after 12 weeks, and again 6 months later. Measurements include muscle strength, lung capacity FVC and FEV1, walking or pushing distance in 6 minutes, flexibility, waist circumference, anxiety levels, bone density, blood lab values, body lean mass, and body fat percentage. These assessments aim to evaluate the impact of the adapted table tennis program on overall physical and mental well-being over time.

Age: 18Years - 75YearsAll GendersPhase Not Applicable
1 location
A

Actively Recruiting

Healthy Volunteer

Researchers are evaluating a new simulation-based ethics education model designed to improve medical students knowledge, moral reasoning, communication skills, and problem-solving abilities. The study involves developing faculty competence, ethics courses, and clinical case scenarios with interdisciplinary experts. Medical students will be randomly assigned to either simulated ethical clinical situations or workshops discussing ethical case scenarios to compare educational outcomes. Participants will be divided into two groups one experiencing a simulated clinical ethical situation with simulation patients as the intervention group, and the other attending workshops discussing clinical ethical case scenarios as the control group. Faculty development and curriculum planning will support these interventions. The study will run over about two years, during which various instruments and strategies will be applied to assess the education models effectiveness. Throughout the study, participants will complete assessments such as the Defining Issues Test, Problem Identification Test, knowledge tests, and clinical ethical decision-making exams. Additional measures include an Objective Structured Clinical Examination and satisfaction questionnaires. These assessments aim to evaluate students ethical reasoning and communication skills. The study is sponsored by Kaohsiung Medical University Chung-Ho Memorial Hospital and includes follow-up until study completion, averaging two years.

Age: 18Years - 65YearsAll GendersPhase Not Applicable
1 location
P

Actively Recruiting

This research aims to develop a safe and systematic exercise assessment and prescription program specifically for cancer survivors who have completed their primary curative treatments at least two months prior. It addresses the challenges cancer patients face when starting exercise due to health risks and seeks to create a personalized, reproducible workflow for exercise prescription based on thorough health evaluations. Participants undergo a comprehensive evaluation led by a physiatrist, including medical history review, cardiovascular risk profiling, functional physical fitness tests, cardiopulmonary exercise testing CPET, and musculoskeletal ultrasound if needed. Based on these assessments, participants are classified into high, moderate, or low exercise risk groups and receive individualized exercise prescriptions involving aerobic, resistance, and flexibility training tailored in intensity, frequency, and duration. The study involves ongoing exercise with continuous monitoring and adjustments. During the study, participants track their exercise progress weekly using training logs and report every four weeks. Full reassessments occur at baseline, three months, and six months to safely adjust exercise prescriptions. Researchers measure outcomes such as handgrip strength, arm curls, chair stands, balance, walking distance, peak oxygen consumption, and quality of life questionnaires. The program includes safety monitoring and data feedback to ensure ongoing participant safety and intervention quality.

Age: 18Years - 80YearsAll GendersPhase Not Applicable
1 location
E

Actively Recruiting

Researchers are evaluating a medicine called survodutide in adults aged 18 and older who have confirmed non-alcoholic steatohepatitis NASH or metabolic-associated steatohepatitis MASH with cirrhosis, and a body mass index BMI of 27 kgm2 or higher, or 25 kgm2 for Asian participants. The study aims to find out if survodutide helps improve liver function and related health outcomes in these individuals. People with other chronic liver diseases or high alcohol intake are not eligible to participate. Participants are randomly assigned to one of two groups one group receives once-weekly injections of survodutide, and the other group receives a placebo injection that looks the same but contains no medicine. Both groups receive counseling to encourage dietary changes and regular exercise. The study is double-blinded, meaning neither participants nor doctors know which treatment is given. The trial lasts up to 4 and a half years, with visits either in person or via video calls scheduled every 2, 4, or 6 weeks for about 17 months, then every 3 months afterwards. Throughout the study, researchers monitor participants health, body weight, and any side effects. They use imaging methods to measure liver parameters and collect symptom questionnaires. The main outcome measured is the time until serious liver-related events occur, such as liver transplant or worsening liver function. Secondary outcomes include changes in liver fibrosis, body weight, blood sugar control, liver stiffness, and other health markers. This thorough monitoring helps compare the effects of survodutide to placebo over the long term.

Age: 18Years +All GendersPhase 3
447 locations
E

Actively Recruiting

Researchers are studying adults aged 18 and older who live with obesity and have a liver disease known as non-alcoholic steatohepatitis NASH or metabolic associated steatohepatitis MASH with moderate or advanced liver fibrosis. The study aims to evaluate whether a medicine called survodutide can improve liver function in people with these conditions. It is a Phase III, randomized, double-blind, placebo-controlled trial conducted at multiple centers. Participants are randomly assigned to one of two groups one receives weekly injections of survodutide, and the other receives placebo injections that look the same but contain no medicine. The survodutide dose is gradually increased until reaching the target dose. All participants receive counseling on diet and exercise. The study includes two parts the first focuses on the effect of survodutide on NASH and fibrosis over one year, and the second assesses its long-term safety and effectiveness over up to seven years. Participants stay in the study for up to seven years, attending regular visits either in person or remotely via video call. Visits occur every two weeks initially, then every four to six weeks, and later every three months. Doctors monitor health, record any side effects, and measure body weight and digestive symptoms. Liver assessments include imaging and biopsies at selected visits. Participants also complete questionnaires about symptoms and quality of life. Researchers compare results between the groups to assess the medicines effects on liver health and related outcomes.

Age: 18Years +All GendersPhase 3
532 locations
L

Actively Recruiting

This research evaluates the long-term safety and efficacy of lentiviral-based gene-edited immune cell therapy in patients who have previously received this treatment. The study responds to health authority guidelines recommending a 15-year follow-up to monitor delayed adverse events after gene therapy. It focuses on patients treated with therapies manufactured by Pell Bio-Med Technology Co. Ltd. and aims to collect extended safety and effectiveness data. Participants enroll in this observational study after completing or withdrawing early from a prior gene-edited immune cell therapy protocol. Enrollment can occur immediately after the previous treatment or at any time within 15 years following the last infusion. Some participants may join other Pell gene-edited immune cell therapy studies while remaining inactive in this follow-up study. Throughout the 15-year follow-up, researchers monitor for delayed adverse events potentially related to previous therapy. Assessments include testing for replication-competent lentivirus and tracking the persistence of gene-edited immune cells in blood using qPCR and flow cytometry. This long-term monitoring helps evaluate both safety and sustained efficacy, with the entire participation lasting up to 15 years.

All AgesAll Genders
5 locations
S

Actively Recruiting

Overactive bladder OAB is a common condition causing urinary urgency, frequent urination, and nighttime urination, which can greatly impact quality of life. Women with metabolic syndrome, a group of conditions including high blood pressure, high blood sugar, abnormal cholesterol, and abdominal obesity, may have a higher risk of OAB. This study evaluates the safety and effectiveness of low-energy extracorporeal shock wave therapy LiESWT, a non-invasive treatment, in women with metabolic syndrome-associated OAB. Participants are randomly assigned to receive either active LiESWT or a sham inactive procedure that mimics the treatment without delivering shock waves. LiESWT is applied using a focused shock wave device at a specific energy and frequency setting, with 3,000 pulses per session directed at the bladder area. The study is double-blind and sham-controlled to compare outcomes between groups. Participants will complete validated questionnaires measuring OAB symptoms, urinary distress, and impact on daily life at baseline and follow-ups up to 24 weeks. Additional assessments include urine flow rates, bladder ultrasound to measure residual urine volume, and a 3-day voiding diary to track urine output and frequency. These measures will help determine changes in symptoms and bladder function over the study period.

Age: 20Years - 75YearsFEMALEPhase Not Applicable
1 location
P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of ADI-PEG 20 in adults with Nonalcoholic Steatohepatitis NASH, a liver condition characterized by fat buildup and inflammation. This phase 2A clinical trial compares ADI-PEG 20 with a placebo to understand its impact on liver fat reduction. The study includes careful monitoring of side effects and laboratory tests to ensure participant safety. Participants receive weekly doses of ADI-PEG 20 or placebo via intramuscular injection at 36 mgm2. The trial is randomized and double-blind, meaning neither participants nor researchers know who receives the active drug or placebo. The treatment period lasts 24 weeks, during which liver fat changes are assessed using MRI-PDFF imaging. An independent committee oversees safety by reviewing adverse events and clinical data. During the study, participants undergo regular health evaluations including vital signs, body weight checks, ECGs, and blood tests. Liver fat levels are measured at the start and at week 24 to assess treatment effects. Safety is monitored continuously through adverse event reporting and laboratory tests. The total participation time spans 24 weeks, with ongoing review of safety and efficacy outcomes throughout.

Age: 18Years - 80YearsAll GendersPhase 2
10 locations
P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of a new drug called daraxonrasib compared to the chemotherapy drug docetaxel in patients with non-small cell lung cancer NSCLC who have specific RAS gene mutations and have already received treatment. This global, randomized, open-label Phase 3 study aims to find out if daraxonrasib can improve how long patients live without their cancer worsening or overall survival compared to standard chemotherapy. Participants are randomly assigned to one of two groups one group receives daraxonrasib as oral tablets, and the other group receives docetaxel through intravenous infusion. The study follows patients over several years to compare the outcomes of these treatments. Patients receive treatment according to their assigned group and are monitored regularly throughout the study period. During the study, participants will have assessments including scans to measure tumor size, tests to check organ function, and questionnaires about quality of life. Researchers will evaluate progression-free survival and overall survival as main outcomes, along with the safety and tolerability of the treatments. The study lasts up to approximately four years, with ongoing monitoring of patients health and treatment responses.

Age: 18Years +All GendersPhase 3
158 locations

1-10 of 13

1